Published: Sat, December 09, 2017
Business | By Max Garcia

Teva Pharmaceutical Industries (TEVA) PT Set at $10.00 by Cantor Fitzgerald


According to 19 analysts, the Average Revenue Estimate for the current Fiscal quarter is $5.32 Billion and the Low Revenue estimate is $5.22 Billion, while the High Revenue estimate is $5.63 Billion.

Today's opinion, the overall signal based on where the price lies in reference to the common interpretation of all 13 studies, for Teva Pharmaceutical Industries Ltd (TEVVF) is Hold.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, May 11th. The same analysts are predicting that the company shares will trade to $14.43 within the next 12-18 months. Citigroup Inc reiterated a "buy" rating and set a $47.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 7th.

Several brokerages have weighed in on TEVA. The firm now has a "hold" rating on the stock. On Monday, August 10 the stock rating was maintained by Goldman Sachs with "Buy".

The steps may aid Schultz, who last month took the helm at the world's biggest maker of copycat drugs, in stemming a rout that has seen Teva's stock plummet to its lowest in 17 years. BTIG Research upgraded the stock to "Buy" rating in Monday, September 11 report. The firm has "Hold" rating by Mizuho given on Thursday, October 26. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and fourteen have assigned a buy rating to the company. The stock now has an average rating of "Hold" and an average price target of $21.65. Security National Bank of Sioux City Iowa IA increased its holdings in Teva Pharmaceutical Industries by 0.4% in the 2nd quarter.

According to 21 stock analysts, Mylan N.V., is being kept at an average Outperform, rating, with at least 4.77% of shares outstanding that are now legally short sold. Finally, Nordea Investment Management AB increased its position in shares of Teva Pharmaceutical Industries by 2.5% during the second quarter. TEVA has diverse figures for different time frames; starting from week's performance it is giving positive returns of 1.21% in last five regular trading sessions.

Teva Pharmaceutical Industries Ltd (TEVVF)'s Williams Percent Range or 14 day Williams %R presently is at -35.31.

Teva Pharmaceutical Industries Limited Underpriced by 153.33% . During the last month, the stock has changed 0.06% and performed 6.21% over the last 6 months.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up $1.05 during trading hours on Friday, reaching $16.05. The stock exchanged hands with 22,046,712 numbers of shares compared to its average daily volume of 25.26M shares.

The company's ATR (Average True Range) is 0.44.

Teva Pharmaceutical Industries Ltd is considering cutting up to 10,000 jobs as CEO Kare Schultz seeks to reduce $1.5 billion to $2 billion in costs over the next two years, Bloomberg reported, citing people familiar with the matter.

For the most active stocks in the market, it is highly important to check the outstanding shares of the company. Stockholders of record on Tuesday, November 28th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.12%. The ex-dividend date of this dividend is Monday, November 27th.

The PEG ratio for Teva Pharmaceutical Industries Limited is now *TBA.

TRADEMARK VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of worldwide copyright and trademark laws. The correct version of this report can be viewed at https://stocknewstimes.com/2017/12/08/5-33-billion-in-sales-expected-for-teva-pharmaceutical-industries-limited-teva-this-quarter.html.

Seeking ways to pay back nearly $35 billion in debt, Teva has been selling assets, closing factories and firing employees in recent quarters following an ill-timed $40.5 billion bet on the generics industry.

Like this: